NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis $0.60 0.00 (0.00%) As of 09/22/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASLAN Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.60▼$0.6050-Day Range$0.60▼$0.6052-Week Range$0.48▼$25.44VolumeN/AAverage Volume122,322 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ASLAN Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for diseases in immunology and oncology. The company was incorporated in Singapore and has historically operated across Singapore, the United States and other international markets. ASLAN’s principal development program was eblasakimab, a monoclonal antibody designed to block signaling through the interleukin-13 receptor alpha 1 pathway. The program was investigated as a potential treatment for atopic dermatitis and other inflammatory conditions. ASLAN also developed ASLAN003, an oral small-molecule therapy targeting dihydroorotate dehydrogenase that was evaluated for potential use in oncology, including acute myeloid leukemia. ASLAN Pharmaceuticals was founded in 2010 and became publicly traded on the Nasdaq under the symbol ASLN in 2018. The company was historically led by Chief Executive Officer Carl Firth. Its development activities and corporate strategy have evolved as it assessed clinical results, partnerships and available resources.AI Generated. May Contain Errors. Read More Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASLN Stock News HeadlinesPublic Health News | Today's Latest Stories | ReutersOctober 3, 2024 | reuters.comASLAN stock tumbles 54% after board votes to liquidateJuly 19, 2024 | msn.comIran War TRUTH: What Two Congressmen Led Me ToTwo private meetings with U.S. Congressmen on March 2nd, three days after the first missiles fell, sent one analyst down an unexpected research trail. The investigation uncovered a coordinated operation, a shadow group running it, and one company sitting at the center of it all.September 24 at 1:00 AM | Behind the Markets (Ad)Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%July 19, 2024 | msn.comWhy ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionJuly 19, 2024 | msn.comASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary LiquidationJuly 17, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to AppealJuly 15, 2024 | globenewswire.comASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International ConferenceMay 21, 2024 | globenewswire.comSee More Headlines ASLN Stock Analysis - Frequently Asked Questions How have ASLN shares performed this year? ASLAN Pharmaceuticals' stock was trading at $0.60 on January 1st, 2026. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) announced its quarterly earnings data on Friday, August, 11th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($6.40) by $5.52. The business earned $12 million during the quarter. When did ASLAN Pharmaceuticals' stock split? ASLAN Pharmaceuticals shares reverse split on the morning of Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an IPO on Friday, May 4th 2018. The company issued 7,500,000 shares at a price of $8.05 per share. Leerink Partners and Piper Jaffray acted as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. Who are ASLAN Pharmaceuticals' major shareholders? ASLAN Pharmaceuticals' top institutional shareholders include Wellington Management Group LLP (107.73%). How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/11/2023Today9/24/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ASLN CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.22 million Net MarginsN/A Pretax Margin-290.83% Return on Equity-8,454.87% Return on Assets-121.60% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$12 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.09Miscellaneous Outstanding Shares2,044,000Free Float1,948,000Market Cap$1.23 million OptionableNo Data Beta1.40 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ASLN) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredCongress Passes Landmark Digital Asset Law Wall Street Is WatchingThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredWall Street Legend: “I've discovered a fatal flaw built into Elon's AI model”Wall Street veteran Marc Chaikin says he's found a fatal flaw built into Elon Musk's AI model and every fronti...Chaikin Analytics | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredThe AI Infrastructure Rush Is ON — Watch VDTAVertical Data Inc. (OTCQB: VDTA) is targeting the layers beneath the AI boom - GPU hardware and financing, man...Trading Wire | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASLN Stock Alerts